Reports Q1 revenue $3.1M, consensus $3.23M. CEO Roger Jeffs said: “With the FDA’s PDUFA goal date on the YUTREPIA NDA just over two weeks away, we remain focused on ensuring that we are prepared to make YUTREPIA commercially available in the quickest time possible if granted full approval. We continue to believe that YUTREPIA has the potential to be the prostacyclin of first choice for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Technologies Updates Audit Report for March 2025
- Liquidia price target raised to $36 from $34 at Scotiabank
- Court dismisses United Therapeutics’ dispute against Liquidia
- Positive Outlook for Liquidia Technologies: Buy Rating Affirmed Following Legal Victory and Anticipated FDA Approval
- Liquidia rallies after judge rules against bid to delay Yutrepia